Coherus BioSciences (CHRS) Set to Announce Earnings on Thursday

Coherus BioSciences (NASDAQ:CHRS) is scheduled to release its earnings data after the market closes on Thursday, August 8th. Analysts expect Coherus BioSciences to post earnings of ($0.21) per share for the quarter.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The firm had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same quarter last year, the firm posted ($0.89) EPS. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Stock Down 4.5 %

CHRS traded down $0.07 during trading on Friday, reaching $1.37. 167,012 shares of the company’s stock were exchanged, compared to its average volume of 2,764,547. Coherus BioSciences has a fifty-two week low of $1.25 and a fifty-two week high of $5.47. The business has a 50 day moving average price of $1.66 and a 200 day moving average price of $2.08. The company has a market capitalization of $156.61 million, a P/E ratio of -1.83 and a beta of 0.60.

Analysts Set New Price Targets

A number of research firms have weighed in on CHRS. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a research note on Friday, May 24th. Robert W. Baird decreased their price target on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating on the stock in a research note on Monday, July 1st. Truist Financial decreased their price target on shares of Coherus BioSciences from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, StockNews.com cut Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Friday, July 26th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Coherus BioSciences has a consensus rating of “Moderate Buy” and an average price target of $8.00.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.